By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
IndebtaIndebta
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
9
Notification Show More
News
Iranians seize more daily freedoms after war
4 hours ago
News
Lebanon’s president warns Iran against ‘interference’ over Hizbollah
5 hours ago
News
South Korea’s former first lady in solitary confinement after bribery arrest
10 hours ago
Videos
Tesla is a company entering, ‘a golden age,’ Wedbush’s Dan Ives says
19 hours ago
Videos
Why manufacturing is so hard in the U.S.
19 hours ago
News
Intrusion Inc. (INTZ) Q2 2025 Earnings Call Transcript
20 hours ago
Videos
LIVE: President Trump visits the Federal Reserve
2 days ago
Videos
How Blackstone became a major U.S. landlord
2 days ago
News
Mercury Systems, Inc. (MRCY) Q4 2025 Earnings Call Transcript
2 days ago
Aa
IndebtaIndebta
Aa
  • Banking
  • Credit Cards
  • Loans
  • Dept Management
  • Mortgage
  • Markets
  • Investing
  • Small Business
  • Videos
  • Home
  • News
  • Banking
  • Credit Cards
  • Loans
  • Mortgage
  • Investing
  • Markets
    • Stocks
    • Commodities
    • Crypto
    • Forex
  • Videos
  • More
    • Finance
    • Dept Management
    • Small Business
Follow US
Indebta > Markets > Stocks > Flying high on obesity success, Novo’s appetite for deals grows
Stocks

Flying high on obesity success, Novo’s appetite for deals grows

News Room
Last updated: 2023/05/07 at 3:48 AM
By News Room
Share
3 Min Read
SHARE

© Reuters. FILE PHOTO: A selection of injector pens for the Wegovy weight loss drug are shown in this photo illustration in Chicago, Illinois, U.S., March 31, 2023. REUTERS/Jim Vondruska/Illustration/File Photo

By Natalie Grover

LONDON (Reuters) – Buoyed by the success of its diabetes and obesity drugs, Novo Nordisk (NYSE:) is on the prowl for partnerships and deals to beef up its pipeline, a senior company executive said on Thursday.

John McDonald, corporate vice president of global R&D business development, said the Danish drugmaker aims to shed its image of being a company that tends to “window shop”, but hardly ever presses the trigger on deals.

Its interest is largely in areas it has already invested in, including diabetes, obesity, cardiovascular disease and gene therapies, he said on a panel at the LSX World Congress conference.

Since launching its popular Wegovy weight-loss drug in the United States in June 2021, Novo’s shares have soared by 140%.

It overtook Nestle in March to become Europe’s second-most valuable listed company worth almost 340 billion euro ($374.5 billion) after LVMH.

The company has traditionally taken a wait-and-see approach to deals, often waiting for drugs to have success in later-stage trials before going for a deal.

“We’re not doing that anymore,” McDonald said. “Instead of waiting and asking for data and trying to see more and more and more, we’ll go earlier.”

For instance, the company might in future bet on five early-stage studies, rather than one-mid-stage one, he added.

Since joining the drugmaker in 2018, the company has grown its business development capacity.

“If you look at some of our competitors, there are hundreds of people in business development … and we probably have 25,” he said.

“We’re growing, but … we’re at the capacity where we can meet the needs and desires of what we see on the horizon today.”

In recent years, the company has bought blood disorders-focused Forma Therapeutics for $1.1 billion, diabetes firm Emisphere Technologies for $1.8 billion and cardiovascular disease specialist Corvidia Therapeutics for $725 million.

($1 = 0.9078 euros)

Read the full article here

News Room May 7, 2023 May 7, 2023
Share this Article
Facebook Twitter Copy Link Print
Leave a comment Leave a comment

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Finance Weekly Newsletter

Join now for the latest news, tips, and analysis about personal finance, credit cards, dept management, and many more from our experts.
Join Now
Iranians seize more daily freedoms after war

Before the 12-day war between Israel and Iran, Nima, a Tehran dog…

Lebanon’s president warns Iran against ‘interference’ over Hizbollah

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

South Korea’s former first lady in solitary confinement after bribery arrest

Unlock the Editor’s Digest for freeRoula Khalaf, Editor of the FT, selects…

Tesla is a company entering, ‘a golden age,’ Wedbush’s Dan Ives says

Watch full video on YouTube

Why manufacturing is so hard in the U.S.

Watch full video on YouTube

- Advertisement -
Ad imageAd image

You Might Also Like

Stocks

Playa Hotels & Resorts (NASDAQ:PLYA) Delivers Strong Q4 Numbers By Stock Story

By News Room
Stocks

ON24 (NYSE:ONTF) Posts Better-Than-Expected Sales In Q4 By Stock Story

By News Room
Stocks

Evolent Health shares leap on Q4 earnings beat and upbeat guidance By Investing.com

By News Room
Stocks

Chuy’s (NASDAQ:CHUY) Reports Q4 In Line With Expectations But Stock Drops

By News Room
Stocks

Red River Bancshares raises dividend to $0.09 per share

By News Room
Stocks

Ecolab appoints Microsoft executive to board

By News Room
Stocks

Semilux secures $50 million equity deal with White Lion Capital

By News Room
Stocks

US government debt trajectory to push long-term yields higher, says PIMCO

By News Room
Facebook Twitter Pinterest Youtube Instagram
Company
  • Privacy Policy
  • Terms & Conditions
  • Press Release
  • Contact
  • Advertisement
More Info
  • Newsletter
  • Market Data
  • Credit Cards
  • Videos

Sign Up For Free

Subscribe to our newsletter and don't miss out on our programs, webinars and trainings.

I have read and agree to the terms & conditions
Join Community

2023 © Indepta.com. All Rights Reserved.

Welcome Back!

Sign in to your account

Lost your password?